Precede Biosciences has raised $83.0 million in new funding, an investment aimed at accelerating its mission to transform disease understanding and treatment. The company was founded to address significant gaps in the medical and research community's collective ability to access and comprehend disease-defining biology precisely when it matters most. To tackle this critical challenge, Precede Bio has developed a novel, simple blood test designed to uncover actionable disease-defining transcriptional biology.
At the core of Precede Biosciences' approach is a unique genome-wide platform. This technology profiles circulating chromatin and the DNA methylome, enabling high-resolution insights into the dynamic activity of individual genes and pathways within diseased tissues. Remarkably, this detailed biological information can be extracted from just 1mL of plasma, offering a minimally invasive method for deep disease characterization.
This significant capital infusion is poised to accelerate Precede Biosciences' strategic initiatives and expand its operational footprint. The company plans to use the funds to further develop its unique genome-wide platform, enhance its research and development capabilities, and strengthen its collaborations with developers of new medicines. By advancing its own diagnostic tests and supporting external drug development efforts, Precede Biosciences aims to enhance the success rate of new medicine development and bring its innovative solutions to a broader market.
Looking ahead, Precede Biosciences is focused on a future where new therapeutic interventions are developed more frequently and effectively. The company envisions a world where individuals can receive precise, minimally invasive diagnoses and treatments tailored specifically to the unique biology of their disease, ultimately improving patient outcomes globally.
